NextCure, Inc.
Clinical trials sponsored by NextCure, Inc., explained in plain language.
Biopharma developing immunotherapies for cancer.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New targeted drug LNCB74 enters human trials for Hard-to-Treat cancers Results expected Dec 2026 (estimated)
-
New targeted drug LNCB74 enters human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests a new drug, LNCB74, in people with advanced solid tumors (ovarian, breast, endometrial, bile duct, or lung cancer) that have not responded to standard treatments. The drug is designed to deliver a cancer-killing agent directly to tumor cells. The main…
Phase 1 • Sponsor: NextCure, Inc. • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
New drug SIM0505 enters first human tests for advanced cancers
Disease control Recruiting nowThis early-stage trial is testing an experimental drug called SIM0505 in adults with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check for any early signs that the drug shrinks tumors. About 414 participants will re…
Phase 1 • Sponsor: NextCure, Inc. • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC